Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, with a familial recurrence risk of 3%. Despite performing an optimal surgical repair, TOF patients may feature a poor medium and long-term survival rate: atrial re-entrant tachycardia will develop in more than 30% of patients and high-grade ventricular arrhythmias will be seen in about 10% of patients.
These life-threatening arrhythmias and consequent sudden death continue to represent serious complications following TOF repair. Radiofrequency ablation and implantable cardioverter defibrillator are today the most effective therapeutic tools in these subjects, while the administration of antiarrhythmic drugs (Ib agents, beta blockers, and amiodarone), widely prescribed in the past, is now limited to few conditions. However pharmacological therapy still plays a role in the management of those patients who are resistant to the above stated invasive electrophysiological treatments.
Keywords: Tetralogy of Fallot, congenital heart disease, sudden death, follow up, ventricular arrhythmias, antiarrhythmic drugs.
Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
Current Cardiology Reviews Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials